The antihypertensive effectiveness and safety of dual raas blockade with aliskiren and valsartan

Drugs of Today

Volumn 46, Issue 3, 2010, Pages 151-162

  Chrysant, Steve G ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN II; ATENOLOL; CELECOXIB; CIMETIDINE; CREATININE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; MEVINOLIN; PLACEBO; RAMIPRIL; RENIN; VALSARTAN; WARFARIN;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; HYPERKALEMIA; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UREA NITROGEN BLOOD LEVEL;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 77954108460     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.3.1437245     Document Type: Review

References (47)

1. Laragh, J.H.,Baer, L.,Brunner, H.R.,Buhler, F.R.,Sealey, J.E.,Vaughan, E.D. Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972, 52(5): 633-52.
2. Westermann, D., Riad, A., Lettau, O. et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008, 52(6): 1068-75.
3. Dzau, V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005, 23(Suppl. 1): S9-17.
4. Verdecchia, P., Angeli, F., Mazzotta, G., Gentile, G., Reboldi, G. The renin angiotensin system in the development of cardiovascular disease: Role of aliskiren in risk reduction. Vasc Health Risk Manag 2008, 4(5): 971-81.
5. Chrysant, S.G. vascular remodeling: The role of angiotensin-converting enzyme inhibitors. Am Heart J 1998, 135(2 Pt 2): S21-30.
6. Thybo, N.K., Stephens, N., Cooper, A., Aalkjaer, C., Heagerty, A.M., Mulvany, M.J. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995, 25(4 Pt 1): 474-81.
7. Dahlof, B., Devereux, R.B., Kjeldsen, S.E. et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359(9311): 995-1003.
8. Turnbull, F., Neal, B., Pfeffer, M. et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007, 25(7): 951-8.
9. van den Meiracker, A.H., Man in 't Veld, A.J., Admiraal, P.H. et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? J Hypertens 1992, 10(8): 803-12.
10. van de Wal, R.M., Plokker, H.W., Lok, D.J. et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006, 106(3): 367-72.
11. Mooser, V., Nussberger, J., Juillerat, L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990, 15(2): 276-82.
12. Hollenberg, N.K., Fisher, N.D., Price, D.A. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological Interruption of the renin system. Hypertension 1998, 32(3): 387-92.
13. Menard, J., Campbell, D.J., Azizi, M., Gonzales, M.F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997, 96(9): 3072-8.
14. Azizi, M., Guyene, T.T., Chatellier, G., Wargon, M., Menard, J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997, 29(2): 634-40.
15. Mogensen, C.E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R.W., Cooper, M.E. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321(7274): 1440-4.
16. Izzo, J.L., Weiberg, M.S., Hainer, J.W., Kerkering, J., Tou, C.K. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: The AMAZE trials. J Clin Hypertens 2004, 6(9): 485-93.
17. Yusuf, S., Teo, K.K., Pogue, J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15): 1547-59.
18. Phillips, C.O., Kashani, A., Ko, D.K., Francis, G., Krumholz, H.M. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme Inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials. Arch Intern Med 2007, 167(18): 1930-6.
19. Lakhdar, R., Al-Mallah, M.H., Lanfear, D.E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: A systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008, 14(3): 181-8.
20. Doulton, T.W., He, F.J., MacGregor, G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45(5): 880-6.
21. Messerli, F.H. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009, 53(6): 468-70.
22. 1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004, 15(12): 3126-33.
23. Frampton, J.E., Curran, M.P. Aliskiren: A review of its use in the management of hypertension. Drugs 2007, 67(12): 1767-92.
24. Dieterle, W., Corynen, S., Mann, J. Effects of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004, 58(4): 433-6.
25. Vaidyanathan, S., Valencia, J., Kemp, C. et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006, 60(11): 1343-56.
26. Dieterle, W., Corynen, S., Vaidyanathan, S., Mann, J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005, 43(11): 527-35.
27. Vaidyanathan, S., Bigler, H., Yeh, C., Bizot, M.N., Dieterich, H.A., Howard, D., Dole, W.P. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007, 46(8): 661-75.
28. Kushiro, T., Irakura, H., Abo, Y., Gotou, H., Terao, S., Keefe, D.L. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006, 29(12): 997-1005.
29. Oh, B.H., Mitchell, J., Herron, J.R., Chung, J., Khan, M., Keefe, D.L. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007, 49(11): 1157-63.
30. Pool, J.L., Schmieder, R.E., Azizi, M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007, 20(1): 11-20.
31. Oparil, S., Yarows, S.A., Patel, S., Fang, H., Zhang, J., Satlin, A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007, 370(9583): 221-9.
32. Chrysant, S.G., Murray, A.V., Hoppe, U.C., Dattani, D., Patel, S., Hsu, H., Zhang, J. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: A 6-month interim analysis. Curr Med Res Opin 2008, 24(4): 1039-47.
33. Stanton, A., Jensen, C., Nussberger, J., O'Brien, E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42(6): 1137-43.
34. Gradman, A.H., Schmieden R.E., Lins, R.L., Nussberger, J., Chiang, Y., Bedigian, M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111(8): 1012-8.
35. Solomon, S.D., Appelbaum, E., Manning, W.J. et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119(4): 530-7.
36. Parving, H.H., Persson, F., Lewis, J.B., Lewis, E.J., Hollenberg, N.K., AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358(23): 2433-46.
37. Villamil, A., Chrysant, S.G., Calhoun, D., Schober, B., Hsu, H., Matrisciano-Dimichino, L., Zhang, J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007, 25(1): 217-26.
38. O'Brien, E., Barton, J., Nussberger, J., Mulcahy, D., Jensen, C., Dicker, P., Stanton, A. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007, 49(2): 276-84.
39. Weir, M.R., Bush, C., Anderson, D.R., Zhang, J., Keefe, D., Satlin, A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis. J Am Soc Hypertens 2007, 1(4): 264-77.
40. Persson, F., Rossing, P., Reinhard, H. et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009, 32(10): 1873-9.
41. Chrysant, S.G., Chrysant, G.S. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 2006, 8(4): 261-268.
42. Chrysant, S.G. Current status of dual renin angiotensin aldosterone system blockade for the treatment of cardiovascular diseases. Am J Cardiol (in press): DOI: 10.1016/j.amj-card.2009.11.044.
43. Verdecchia, P., Sleight, P., Mancia, G. et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. Circulation 2009, 120(14): 1380-9.
44. Alderman, M.H., Madhaven, S., Ooi, W.L., Cohen, H., Sealey, J.E., Laragh, J.H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324(16): 1098-104.
45. Brunner, H.R., Laragh, J.H., Baer, L. et al. Essential hypertension: Renin and aldosterone, heart attack and stroke. N Engl J Med 1972, 286(9): 441-9.
46. Xu, D., Borges, G.R., Grobe, J.L., Pelham, C.J., Yang, B., Sigmund, C.D. Preservation of intracellular renin expression is insufficient to compensate for genetic loss of secreted renin. Hypertension 2009, 54(6): 1240-7.
47. Lambers Heerspink, H.J., Perkovic, V., De Zeeuw, D. Renal and cardio-protective effects of direct renin inhibition: A systematic literature review. J Hypertens 2009, 27(12): 2321-31.